Clinical Study Number | 1152.10 |
---|---|
Study Indication | Colorectal Neoplasms |
Product | Sibrotuzumab |
Generic Name | Sibrotuzumab |
Lab Code | |
Clinical Phase | IIa |
Study Title |
A phase II uncontrolled study to evaluate the antitumour activity and safety of intravenous BIBH 1, administered in a weekly dose of 100 mg in 12 weeks, in patients with metastatic colorectal cancer. |
Study Document | Trial synopsis 1152.10_CO english |
Clinical Study Number | 1152.3 |
---|---|
Study Indication | Carcinoma, Non-Small-Cell Lung |
Product | Sibrotuzumab |
Generic Name | Sibrotuzumab |
Lab Code | |
Clinical Phase | I |
Study Title |
A Phase I Single Dose Escalation Study of BIBH 1 in Patients with Non-Small Cell Lung Cancer Scheduled for Resection |
Study Document | Trial synopsis 1152.3_CO english |
Clinical Study Number | 1152.6 |
---|---|
Study Indication | Carcinoma, Non-Small-Cell Lung |
Product | Sibrotuzumab |
Generic Name | Sibrotuzumab |
Lab Code | |
Clinical Phase | I |
Study Title |
A Phase I Single Dose Escalation Study of 131 I-Sibrotuzumab in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer |
Study Document | Trial synopsis 1152.6_CO english |
Download our Policy on Transparency and Publication of Clinical Study Data.Download
Browse our clinical study overview and read study synopses and lay summaries.
Learn about our process of responsible sharing of clinical study data and documents and request access to data and documents.